… randomized, double-blind, phase 2 part of KEYNOTE-022 compared the efficacy of the triplet
combination of pembrolizumab, dabrafenib, and trametinib … with dabrafenib and trametinib.…

… conducted the double-blind, randomized, phase 2 part of KEYNOTE-022, … of pembrolizumab,
dabrafenib and trametinib with placebo, … Part 3 of the multicenter phase 1/2 KEYNOTE-022 …

… data from the phase 2 SWOG S1320 study, which showed … part 3 of KEYNOTE-022, with a
numerically improved PFS and DOR seen with pembrolizumab plus dabrafenib and trametinib …

… 1) antibody pembrolizumab in combination with dabrafenib and … of the randomized,
double-blind, placebo-controlled part 3, … -i, the phase II KEYNOTE-022 and phase III IMspire150 …

… pembrolizumab plus matching placebo), double-blind phase … from the randomised phase II
part of the KEYNOTE-022 trial [… arm of pembrolizumab, dabrafenib and trametinib, compared …

… of pembrolizumab in combination with dabrafenib and … advanced melanoma, the randomized,
double-blind part 3 of the trial was … In part 3 of the KEYNOTE-022 trial, 120 patients with …

… with pembrolizumab and intermittent dabrafenib and trametinib (p=0.17). The 2-year and 3-…
of the control arm, two of these trials, the COMBI-I and the KEYNOTE-022, did not meet their …

… pembrolizumab combined with BRAF inhibitor dabrafenib … of this study were in concordance
to findings the Keynote-022 trial [11… is a phase 2 study, in which patients were randomized to …

… Patients were randomized to treatment with 6 weeks of neoadjuvant pembrolizumab … week
of dabrafenib plus trametinib followed by pembrolizumab; n = 20) or concurrent triple therapy (…

… The randomized, double-blind, phase 2 KEYNOTE-002 study compared … The phase 2
KEYNOTE-022 trial of pembrolizumab plus dabrafenib and trametinib (triplet therapy) in patients …